We aim to provide you with the best information to make an informed decision about your vision from your suitability to the treatment options available.
GLP-1 Agonists, your eyes and vision
Understand how GLP‑1 weight loss drugs such as Ozempic, Wegovy and Mounjaro can impact your eyes. Learn about risks like diabetic retinopathy, blurred vision, dry eye and rare optic nerve problems, and how regular eye checks at Laser Vision SA can help protect your sight.
GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro have become increasingly popular for their ability to help people lose weight by reducing appetite and slowing digestion. They are also being increasingly contemplated for cardiac health and some evidence is beginning to appear for their ability to provided beneficial effects in other areas:
- 14% reduction in the risk of heart attacks, strokes, and cardiovascular death possibly by improved blood pressure, lower cholesterol profiles, and decrease blood vessel inflammation.
- A reduction in the progression of chronic kidney disease (CKD) and reduce the risk of kidney failure.
- disease caused by fat buildup
- Dementia Risk Reduction:
- Curbing Addictions🛌 Physical Function & Sleep
- Sleep Apnea Relief.
- Lowering overall inflammation helps ease obesity-related organ stress, reducing joint pain and blood clot risks
Potential Vision-Related Risks
1. Diabetic Retinopathy Progression
Ozempic and similar drugs were initially created for diabetes management, but rapid blood sugar changes can sometimes worsen diabetic retinopathy—a condition where high blood sugar damages the blood vessels in the retina. Some studies suggest that fast weight loss and blood sugar drops may accelerate retinal complications in those with existing diabetes (1)
Some users report experiencing temporary blurred vision after starting these medications. This may be due to fluid shifts in the eye, changes in blood sugar levels, or the way the drug interacts with metabolism.
3. Increased Risk of Dry Eyes
Weight loss medications can alter hydration levels and metabolism, sometimes leading to dry eyes, irritation, and discomfort. This can be particularly bothersome for those who already suffer from dry eye syndrome.
4. Potential for Optic Neuropathy
The Australian Therapeutic Goods Administration (TGA) has issued a notification about the potential association between GLP-1 receptor agonists and non-arteritic ischaemic optic neuropathy (NAION), a rare condition that affects the optic nerve and can lead to sudden and if left untreated permanent vision loss. The exact cause isn’t well understood, but it may be related to changes in circulation and nerve function. As always sudden partial or full vision loss should be treated as a clinical emergency with rapid assessment by optometrist of ophthalmologist (2)
https://www.tga.gov.au/news/safety-updates/glp-1-ras-and-rare-vision-disorder
Protecting Your Eye Health While Using Weight Loss Medications
If you're considering or already using a weight loss drug, here are some steps to help safeguard your vision:
- Have a baseline eye exam– If you have diabetes or prediabetes, ensure your eye health is monitored closely, especially in the early days of using the GLP-1 receptor agonsits.
- Watch for vision changes – If you notice sudden blurriness, eye pain, or floaters, consult an optometrist or eye specialist immediately.
- Discuss risks with your doctor – If you have a history of eye conditions, ask your healthcare provider whether weight loss medication is the right choice for you.
Prior to procedures
As GLP-! Agonists slow the emptying of your stomach, you need to let your anaesthetist and surgeon know you are on these drugs prior to any procedure involving sedation or general anaesthetic. You will be asked to fast for longer, or to cease the GLP- ! agonist for some time period prior to your procedure. This is to avoid inhalation of the contents of a slow emptying stomach into the lungs possibly causing poor oxygenation or other anaesthetic complications and later pneumonia
To sum up
Weight loss drugs like GLP-1 receptor agonists can be effective tools for managing weight, but there are some small risks to your eye health. These small risks need to be balanced against the risks to your eye and vision if you do NOT take these drugs. The worse your blood sugar, pressure and cholesterol, and even your sleep apnoea, the greater the risk of eye disease and possibly permanent loss of vision.
The outlined risks are not usually reasons to not take or stop taking GLP-1 Agonists. The risks outline do mean it’s essential to stay informed, monitor any vision changes, and prioritize regular eye checkups to protect your long-term vision.
- Arisa Gonzalez 1 2, Lisa Chastain 3 4, Olga Karasik 1 2, Abdo Asmar 1 2 5, Monika Farhangi 1, Carlos A Alvarez 6, Ishak A Mansi 1 5 Association of GLP1-Receptor Agonists With Diabetic Retinopathy Diabetes Obes Metab 2026 Aug 27.
- Cindy X Cai 1 2, Michelle Hribar 3 4, Sally Baxter 5 6 et al Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy JAMA Ophthalmol 2025 Apr 1;143(4):304-314.